New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
05:40 EDTINCY, NVSNovartis announces Phase III study for Jakavi meets primary endpoint
Novartis announced that a pivotal Phase III trial of Jakavi, ruxolitinib, compared to best available therapy has met its primary endpoint of maintaining hematocrit control without the need for phlebotomy, a procedure to remove blood from the body to reduce the concentration of red blood cells, and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea. The safety profile of Jakavi was generally consistent with previous studies based on initial review of the data. Data from the study will be presented at an upcoming medical congress and submitted to worldwide regulatory authorities this year.
News For NVS;INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 7, 2016
14:27 EDTNVSNovartis' somatic cell therapy receives orphan designation
Subscribe for More Information
February 4, 2016
07:23 EDTNVSGSK will not be pressured into early consumer unit spinoff, Reuters says
Subscribe for More Information
February 2, 2016
11:14 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
07:42 EDTNVSPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
January 29, 2016
07:53 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:37 EDTNVSRadius Health should be bought aggressively at current prices, says Canaccord
Canaccord said they would be aggressive buyers of Radius Health (RDUS) especially at current share prices. The firm cited its partnership with Novartis (NVS), its drug pipeline, and expectations for an FDA filing of abaloparatide in the first quarter of 2016. Canaccord reiterated its Buy rating and $85 price target on Radius Health shares.
January 28, 2016
12:09 EDTNVSRadius Health to hold a conference call
Subscribe for More Information
11:33 EDTINCYOptions with increasing call volume
Subscribe for More Information
09:38 EDTNVSNovartis downgraded to Neutral from Outperform at Exane BNP Paribas
Subscribe for More Information
08:14 EDTINCYIncyte selloff brings long-term buying opportunity, says Jefferies
Subscribe for More Information
08:08 EDTINCYIncyte selloff a buying opportunity, says Leerink
Leerink analyst Michael Schmidt recommends using today's pullback in shares of Incyte after the company announced its decision to stop one arm of its ongoing Phase II trial of ruxolitinib in metastatic colorectal cancer due to futility as a buying opportunity. The study is one of several ongoing trials to evaluate ruxolitinib in various solid tumor indications, the analyst points out. He says that while the news is disappointing, the stock's current valuation reflects very little if any value for ruxolitinib in solid tumor indications. Schmidt lowered his price target for Incyte shares to $118 from $135 and reiterates an Outperform rating on the name. The stock is down 13%, or $9.98, to $65.01 in pre-market trading.
07:43 EDTINCYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte announced that it would stop a Phase-2 study of Ruxolitinib plus regorafenib for R/R metastatic colorectal cancer and high-CRP patients due to insufficient efficacy, Oppenheimer says the data makes the drug's anti-inflammatory properties in solid tumors questionable. However, the firm did not previously include revenue from the drug outside of pancreatic cancer in its estimates. The firm keeps a $129 price target and Outperform rating on the shares.
January 27, 2016
19:30 EDTINCYOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
16:45 EDTINCYIncyte to stop Phase 2 sub-study of ruxolitinib plus regorafenib
Subscribe for More Information
16:33 EDTNVSRadius Health announces clinical collaboration with Novartis
Subscribe for More Information
12:19 EDTNVSPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
05:22 EDTNVSNovartis sees FY16 revenue, core operating income in line with FY15
Group net sales and core operating income in 2016 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition. Generic competition impact on sales is expected to be as much as $3.2B compared to $2.2B in 2015.
05:20 EDTNVSNovartis reports Q4 core EPS $1.14, consensus $1.18
Subscribe for More Information
January 26, 2016
14:32 EDTNVSNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Novartis (NVS), consensus $1.18... Boeing (BA), consensus $1.26... United Technologies (UTX), consensus $1.52... Biogen (BIIB), consensus $4.08... EMC (EMC), consensus 65c... General Dynamics (GD), consensus $2.38... Anthem (ANTM), consensus $1.22... Illinois Tool Works (ITW), consensus $1.21... State Street (STT), consensus $1.18... Norfolk Southern (NSC), consensus $1.24... Progressive (PGR), consensus 47c... St. Jude Medical (STJ), consensus $1.01... Rockwell Automation (ROK), consensus $1.33... Textron (TXT), consensus 83c... Hess (HES), consensus ($1.47)... Cliffs Natural (CLF), consensus (26c).
11:34 EDTNVSJuno, Kite valuations at risk following study, TheStreet's Feuerstein says
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use